Profitability Ratios
| Ratio |
Value |
| GP Margin |
75.0% |
| EBIT Margin |
32.2% |
| EBITDA Margin |
41.9% |
| Operating Margin |
31.2% |
| Pretax Margin |
30.0% |
| Cont. Ops Margin |
25.6% |
| Net Margin |
25.6% |
| Bottom Line Margin |
25.6% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
1.12 |
| Quick Ratio |
0.89 |
| Solvency Ratio |
0.293 |
| Cash Ratio |
0.42 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.66 |
| Forward PEG |
0.66 |
| Price/Book |
5.80 |
| Price/Sales |
4.68 |
| Price/FCF |
14.52 |
| Price/Op Cash Flow |
13.34 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.3204 |
| Debt/Equity |
0.8028 |
| Debt/Capital |
0.4453 |
| Long-Term Debt/Capital |
0.3908 |
| Financial Leverage |
2.51 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
27.26 |
| Operating Cash Flow Ratio |
0.736 |
| Operating Cash Flow/Sales |
35.1% |
| Free Cash Flow/Operating Cash Flow |
91.9% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
3.18 |
| Interest Coverage |
14.3836 |
| Short-Term Operating Cash Flow Coverage |
3.63 |
| Operating Cash Flow Coverage |
0.54 |
| Capital Expenditure Coverage |
12.37 |
| Dividend + Capital Expenditure Coverage |
2.04 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
55.9067% |
| Dividend Yield |
3.0608% |
| Dividend Yield % |
3.0608% |
| Dividend Per Share |
4.2239 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
29.46 |
| EPS |
7.555 |
| Debt/Share |
19.7251 |
| Cash/Share |
5.97 |
| Book Value/Share |
23.99 |
| Tangible BV/Share |
-4.34 |
| Equity/Share |
23.78 |
| Operating Cash Flow/Share |
10.343 |
| Capital Expenditure/Share |
0.836 |
| FCF/Share |
9.507 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.855 |
| Earnings Before Tax/EBIT |
0.963 |
| Price/Fair Value |
5.80 |
| Debt/Market Cap |
0.1312 |
| Effective Tax Rate |
14.6% |
| Enterprise Value Multiple |
12.24 |
NVSEF - Novartis AG